CLINICAL_TRIALS
trial_result
· 2018-11-30
Clinical Trial Update: Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia [Phase 3]
Summary
Phase 3 safety and tolerability study of NBI-98854 for tardive dyskinesia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2018-11-30